Brief Title
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Official Title
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
Brief Summary
The purpose of this study is to test the safety of the study drug, atezolizumab, when
combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC). This study
will help researchers begin to understand whether combining GC with atezolizumab is better,
the same, or worse than the usual approach of using GC alone.
Study Phase
Phase 1/Phase 2
Study Type
Interventional
Primary Outcome
Test the safety of atezolizumab in combination with gemcitabine/cisplatin as assessed by dose limiting toxicity rate.
Secondary Outcome
Relapse-Free Survival
Condition
Bladder Cancer
Intervention
Atezolizumab
Study Arms / Comparison Groups
Atezolizumab, Gemcitabine, Cisplatin
Description: This is a two phase study with a single study arm for each phase. For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously. Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
54
Start Date
December 20, 2016
Completion Date
December 2023
Primary Completion Date
December 2023
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- ECOG Performance Status of 0 or 1
- Required Initial Laboratory Values within 14 days of enrollment:
- Absolute Neutrophil Count ≥ 1500 cells/mm^3
- Lymphocyte count ≥ 300/mm^3
- Platelets ≥ 100,000 cells/mm^3
- Hemoglobin ≥ 9.0 g/dL
- Bilirubin ≤ 1.5 the upper limit of normal (ULN) for the institution For patients
with known Gilbert's disease: bilirubin ≤ 3 x ULN
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN for the
institution.
- For patients in the metastatic cohort with documented liver or bone
metastases: AST and/or ALT ≤ 5.0 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN for the institution
- For patients in the metastatic cohort with documented liver or bone
metastases: alkaline phosphatase ≤ 5 x ULN
- If female of childbearing potential, urine pregnancy test is negative.
- INR and aPTT ≤ 1.5 x ULN if not on therapeutic anticoagulation. Patients
receiving therapeutic anticoagulation should be on a stable dose.
Phase I Cohort
- Archival tumor specimens must be submitted prior to enrollment. Samples collected from
fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases,
and lavage are not acceptable. Acceptable samples include core-needle biopsies for
deep tumor tissue (minimum of three cores) or excisional, incisional, punch, or
forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. If archival tissue
is being used, representative urothelial carcinoma FFPE tumor specimens (tumor blocks
or 30 unstained slides) must be provided. Patients with < 30 slides may be enrolled
after discussion with the principal investigator. Primary or metastatic specimens may
be submitted.
- Subject must agree to undergo two research-directed biopsies during treatment.
- The patient must have measurable disease according to RECIST v1.1 and must have one
site amenable to biopsy that, in the opinion of the investigator and/or interventional
radiologist, is likely to yield acceptable tumor sample for a core biopsy per the
above pathology criteria.
- Life expectancy ≥ 12 weeks
- Histologically or cytologically confirmed urothelial carcinoma (confirmed at the
enrolling institution) of the bladder, ureter, urethra, or renal pelvis. Patients with
mixed histologies are required to have a predominant urothelial component as reviewed
by the pathologist at the treating institution.
- Locally advanced (T4b, any N; any T, N2-3) or metastatic (M1) disease as determined by
the treating investigator
- Estimated glomerular filtration rate ≥ 60 ml/min/1.73m2 using the CKD- EPI equation:
eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993Age°x 1.018 [if female] x
1.159 [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is
-0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and
max indicates the maximum of Scr/k or 1
Phase 2 Cohort
- Pathology: Representative urothelial carcinoma FFPE tumor specimens (tumor blocks or
30 unstained slides). Patients with < 30 slides may be enrolled after discussion with
the principal investigator.
- Muscle invasive urothelial carcinoma of the bladder histologically confirmed at the
enrolling institution. (Urothelial carcinoma invading into the prostatic stroma with
no histologic muscle invasion is allowed provided the extent of disease is confirmed
via imaging and/or EUA.)
- Clinical stage T2-4a;N0/X;M0
- Medically appropriate candidate for radical cystectomy, as per MSK or participating
site Attending Urologic Oncologist
- Estimated glomerular filtration rate ≥ 60 ml/min/1.73m2 using the CKD- EPI equation:
eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993Age°x 1.018 [if female] x
1.159 [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is
-0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and
max indicates the maximum of Scr/k or 1
Exclusion Criteria:
- Evidence of NYHA functional class III or IV heart disease
- Serious intercurrent medical or psychiatric illness, including serious active
infection
- Preexisting sensory grade ≥ 2 neuropathy
- Preexisting grade ≥ 2 hearing loss
- Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of
need for a major surgical procedure during the course of the study. Transurethral
resection or other urinary tract diagnostic procedures, excisional biopsy, or MediPort
placement, are NOT defined as major surgical procedures.
- Any of the following within the 6 months prior to study drug administration:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident, or transient
ischemic attack
- Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.0 grade ≥ 2. However, stable
atrial fibrillation controlled medically or with a device (e.g. pacemaker) or prior
ablation is allowed.
- History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency
syndrome (AIDS)-related illness
- Concurrent treatment on another clinical trial; supportive care trials or
non-treatment trials, e.g. QOL, are allowed
- Pregnancy, lactation, or breast-feeding. Patients must be surgically sterile,
postmenopausal, or must agree to use effective contraception during the period of
therapy and for 5 months after the last dose of atezolizumab. The definition of
effective contraception will be based on the judgment of the principal investigator or
a designated associate. Male patients must be surgically sterile or agree to use
effective contraception. Male patients will be encouraged to notify the study team if
their female partner becomes pregnant while on study.
- History of autoimmune disease, including but not limited to myasthenia gravis,
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, Wegener's granulomatosis, vascular thrombosis associated
with antiphospholipid syndrome, Sjogren's syndrome, Guillain-Barre syndrome, multiple
sclerosis, systemic vasculitis, or glomerulonephritis.
- Patients with history of autoimmune related hypothyroidism on stable dose of
thyroid replacement hormone may be eligible for this study
- Patients with controlled Type I diabetes mellitus on a stable dose of insulin may
be eligible for this study
- History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
pneumonia, etc.), or evidence of active pneumonitis on screening chest computed
tomography (CT) scan
- History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- Patients with active hepatitis B virus (HBV, chronic or acute, defined as having a
positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
antibody
- Patients with past HBV infection or resolved HBV infection (defined as the
presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are
eligible. HBV DNA must be obtained in these patients prior to Cycle 1, Day
1 and confirmed to be negative.
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction is negative for HCV RNA.
- Active tuberculosis or BCG infection
- Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to
hospitalization for complications of infection, bacteremia, or severe pneumonia
- Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1. Abnormal
urinalysis does not constitute signs/symptoms of infection unless urine culture
obtained at screening grows ≥ 100,000 colonies of bacteria. Patients with an ileal
conduit and a urinalysis and/or culture that are abnormal are eligible unless they
have peripheral blood WBC > ULN, fever, or other symptoms suggestive of a urinary
tract infection.
- Therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1
- Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary
tract infection or to prevent chronic obstructive pulmonary disease exacerbation)
are eligible.
- Prior allogeneic stem cell or solid organ transplant
- Administration of intravesical bacillus Calmette-Guerin (BCG) within 4 weeks before
Cycle 1, Day 1
- Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or
anticipation that such a live attenuated vaccine will be required during the study.
- Influenza vaccination should be given during influenza season only (approximately
October to March). Patients must not receive live, attenuated influenza vaccine
(e.g., FluMist ®) within 4 weeks prior to Cycle 1, Day 1 or at any time during
the study.
- AEs from prior anticancer therapy that have not resolved to Grade ≤ 1 except for
alopecia
- Bisphosphonate therapy for symptomatic hypercalcemia
- Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or
osteoporosis) is allowed.
- Known clinically significant liver disease, including active viral, alcoholic, or
other hepatitis; cirrhosis; and inherited liver disease
- Patients with a history of or active bone marrow disorders expected to interfere with
study therapy (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous
leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or
non-secretory myeloma)
- Known primary central nervous system (CNS) malignancy, active or untreated CNS
metastases, symptomatic CNS metastases, and/or leptomeningeal disease
- Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with
dermatologic manifestations only (e.g., patients with psoriatic arthritis would be
excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out
ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical
steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone
0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not
requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids,
biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or render the patient at high risk from treatment
complications
- Malignancies other than the disease under study within 5 years prior to Cycle 1, Day
1, with the exception of those with a negligible risk of metastasis or death and with
expected curative outcome (such as adequately treated carcinoma in situ of the cervix,
basal or squamous cell skin cancer, localized prostate cancer treated surgically with
curative intent, or ductal carcinoma in situ treated surgically with curative intent)
or undergoing active surveillance per standard-of-care management (e.g. prostate
cancer with Gleason score ≤ 6, and prostate-specific antigen [PSA] 10 mg/mL, etc).
Medication-Related Exclusion Criteria:
- Prior treatment with anti-PD-1, and CTLA-4, or anti-a PD-L1 therapeutic antibody or
pathway-targeting agents
- Treatment with systemic immunostimulatory agents (including but not limited to
interferon [IFN]-a or interleukin [IL]-2) within 6 weeks or five half-lives of the
drug (whichever is shorter) prior to Cycle 1, Day 1
- Concomitant use of another investigational agent and/or treatment with an
investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five
half-lives of the investigational product, whichever is longer)
- Treatment with systemic immunosuppressive medications (including but not limited to
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1
- Patients who have received acute, low-dose, systemic immunosuppressant
medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.
- The use of inhaled corticosteroids or mineralocorticoids (e.g., fludrocortisone)
for patients with orthostatic hypotension or adrenocortical insufficiency is
allowed.
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity to Chinese hamster ovary cell products or any component of the
atezolizumab formulation
Phase I Cohort
- Prior chemotherapy or immunotherapy for metastatic urothelial bladder cancer. Prior
neoadjuvant or adjuvant chemotherapy with first progression > 12 months is allowed.
- Any approved anti-cancer therapy within 3 weeks prior to enrollment with the following
exceptions:
- Palliative radiotherapy for bone metastases must be completed > 7 days prior to
baseline imaging and > 21 days prior to cycle 1 day 1 of treatment.
- Hormone replacement therapy or oral contraceptives are permitted
- Administration of intravesical bacillus Calmette-Guerin (BCG) >4 weeks before
Cycle 1, Day 1 is allowed
- Tumor-related pain increased above baseline for 2 weeks and not controlled by a stable
dose of opiates
- Uncontrolled pleural effusion, pericardial effusion, or ascites (indwelling drainage
catheters allowed)
Phase 2 Cohort
- Prior systemic chemotherapy (prior intravesical therapy is allowed)
- Prior radiation therapy to the bladder
- Any approved anti-cancer therapy within 3 weeks prior to enrollment
- Administration of intravesical bacillus Calmette-Guerin (BCG) >4 weeks before Cycle 1,
Day 1 is allowed
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Samuel Funt, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02989584
Organization ID
16-1428
Responsible Party
Sponsor
Study Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Genentech, Inc.
Study Sponsor
Samuel Funt, MD, Principal Investigator, Memorial Sloan Kettering Cancer Center
Verification Date
November 2022